JP2015534981A5 - - Google Patents

Download PDF

Info

Publication number
JP2015534981A5
JP2015534981A5 JP2015537809A JP2015537809A JP2015534981A5 JP 2015534981 A5 JP2015534981 A5 JP 2015534981A5 JP 2015537809 A JP2015537809 A JP 2015537809A JP 2015537809 A JP2015537809 A JP 2015537809A JP 2015534981 A5 JP2015534981 A5 JP 2015534981A5
Authority
JP
Japan
Prior art keywords
dihydropyrazino
pyrazin
methyl
pyridin
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015537809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/065363 external-priority patent/WO2014062878A2/en
Publication of JP2015534981A publication Critical patent/JP2015534981A/ja
Publication of JP2015534981A5 publication Critical patent/JP2015534981A5/ja
Pending legal-status Critical Current

Links

JP2015537809A 2012-10-18 2013-10-17 Torキナーゼ阻害剤を用いた癌の治療 Pending JP2015534981A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715510P 2012-10-18 2012-10-18
US61/715,510 2012-10-18
PCT/US2013/065363 WO2014062878A2 (en) 2012-10-18 2013-10-17 Treatment of cancer with tor kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019012014A Division JP7162543B2 (ja) 2012-10-18 2019-01-28 Torキナーゼ阻害剤を用いた癌の治療

Publications (2)

Publication Number Publication Date
JP2015534981A JP2015534981A (ja) 2015-12-07
JP2015534981A5 true JP2015534981A5 (https=) 2016-11-24

Family

ID=50023830

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015537809A Pending JP2015534981A (ja) 2012-10-18 2013-10-17 Torキナーゼ阻害剤を用いた癌の治療
JP2019012014A Active JP7162543B2 (ja) 2012-10-18 2019-01-28 Torキナーゼ阻害剤を用いた癌の治療
JP2020199055A Pending JP2021050213A (ja) 2012-10-18 2020-11-30 Torキナーゼ阻害剤を用いた癌の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019012014A Active JP7162543B2 (ja) 2012-10-18 2019-01-28 Torキナーゼ阻害剤を用いた癌の治療
JP2020199055A Pending JP2021050213A (ja) 2012-10-18 2020-11-30 Torキナーゼ阻害剤を用いた癌の治療

Country Status (19)

Country Link
US (1) US20140113904A1 (https=)
EP (1) EP2908814B1 (https=)
JP (3) JP2015534981A (https=)
KR (2) KR102267927B1 (https=)
CN (2) CN105050601A (https=)
AU (1) AU2013202768B2 (https=)
BR (1) BR112015008834A2 (https=)
CA (1) CA2888609C (https=)
EA (1) EA029164B1 (https=)
ES (1) ES2777936T3 (https=)
IL (1) IL238326B (https=)
MX (1) MX368407B (https=)
MY (1) MY176599A (https=)
NI (1) NI201500055A (https=)
PH (2) PH12020550858A1 (https=)
SG (2) SG11201502999YA (https=)
UA (1) UA117000C2 (https=)
WO (1) WO2014062878A2 (https=)
ZA (1) ZA201503105B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
PE20151995A1 (es) 2013-01-16 2016-01-13 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
CN108473495B (zh) * 2015-11-20 2022-04-12 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
CN110403943B (zh) * 2019-08-19 2022-05-17 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159582C (zh) * 2001-12-08 2004-07-28 云南大学 一种人体全血或血清总前列腺特征性抗原值,总前列腺特征性抗原灰区值检测方法
GB0509748D0 (en) 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
US20070238745A1 (en) * 2006-04-07 2007-10-11 University Of South Florida PI3K-Akt Pathway Inhibitors
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
MX337906B (es) * 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
EP2349984A1 (en) * 2008-10-17 2011-08-03 Merck & Co. Combination therapy
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
SG10201500511TA (en) * 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling

Similar Documents

Publication Publication Date Title
RU2013108840A (ru) Биомаркерный анализ для детектирования или измерения ингибирования активности tor-киназы
JP2013518890A5 (https=)
JP2015534981A5 (https=)
JP7060694B2 (ja) Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物
AU2013203156B2 (en) Treatment of cancer with TOR kinase inhibitors
RU2015105249A (ru) Ингибиторы mtor киназы для онкологических показаний и заболеваний, связанных с mtor/pi3k/akt путем метаболизма
JP2013508456A5 (https=)
AU2011212927B2 (en) Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
JP2016516817A5 (https=)
JP2016516820A5 (https=)
AU2013203714B2 (en) Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP2016516819A5 (https=)
TW201343166A (zh) 使用tor之激酶抑制劑之癌症治療
JP2021511315A (ja) RETキナーゼ阻害剤としての置換ピラゾロ[3,4−d]ピリミジン化合物
JP2021511330A (ja) Retキナーゼ阻害剤としての置換ピラゾリル[4,3−c]ピリジン化合物
MX2014011077A (es) Tratamiento de cancer con inhibidores de tor cinasa.
TW201343165A (zh) 使用tor激酶抑制劑之癌症治療
CN110721186A (zh) 利用tor激酶抑制剂治疗前列腺癌
HK40013177A (en) Treatment of prostate cancer with tor kinase inhibitors
AU2015213397A1 (en) Treatment of cancer with TOR kinase inhibitors